Rendering

Component: (Network and Table)
Network
2315301 - Disclosure - Segment and Geographic Area Information (Tables)
(http://www.abbvie.com/role/SegmentAndGeographicAreaInformationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Segment Reporting [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Segment Reporting [Abstract]
 
Schedule of net revenues by product
The following tables detail AbbVie's worldwide net revenues:
years ended December 31 (in millions)
2016
 
2015
 
2014
HUMIRA
$
16,078

 
$
14,012

 
$
12,543

IMBRUVICA
1,832

 
754

 

VIEKIRA
1,522

 
1,639

 
48

Lupron
821

 
826

 
778

Synagis
730

 
740

 
835

Synthroid
763

 
755

 
709

Creon
730

 
632

 
516

AndroGel
675

 
694

 
934

Kaletra
549

 
700

 
870

Sevoflurane
428

 
474

 
550

Duodopa
293

 
231

 
220

All other
1,217

 
1,402

 
1,957

Total net revenues
$
25,638

 
$
22,859

 
$
19,960

 
 
Schedule of net revenues to external customers by geographic area
Net revenues to external customers by geographic area, based on product shipment destination, were as follows:
years ended December 31 (in millions)
2016
 
2015
 
2014
United States
$
15,947

 
$
13,561

 
$
10,845

Germany
1,104

 
1,082

 
1,035

United Kingdom
776

 
688

 
722

Japan
770

 
599

 
581

France
713

 
597

 
584

Canada
624

 
551

 
551

Spain
589

 
618

 
534

Italy
523

 
452

 
432

Brazil
355

 
376

 
435

The Netherlands
352

 
334

 
345

All other countries
3,885

 
4,001

 
3,896

Total net revenues
$
25,638

 
$
22,859

 
$
19,960

 
 
Schedule of long-lived assets by geographic area
Long-lived assets, primarily net property and equipment, by geographic area were as follows:

years ended December 31 (in millions)
2016
 
2015
United States and Puerto Rico
$
1,822

 
$
1,868

Europe
504

 
513

All other
278


184

Total long-lived assets
$
2,604

 
$
2,565